دورية أكاديمية
أعرض في EDS

Advances in non-viral mRNA delivery to the spleen.

التفاصيل البيبلوغرافية
العنوان: Advances in non-viral mRNA delivery to the spleen.
المؤلفون: Narasipura EA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. osfenton@unc.edu., Fenton OS; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. osfenton@unc.edu.
المصدر: Biomaterials science [Biomater Sci] 2024 Jun 11; Vol. 12 (12), pp. 3027-3044. Date of Electronic Publication: 2024 Jun 11.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101593571 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-4849 (Electronic) Linking ISSN: 20474830 NLM ISO Abbreviation: Biomater Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, UK : Royal Society of Chemistry
مواضيع طبية MeSH: Spleen*/metabolism , RNA, Messenger*/administration & dosage , RNA, Messenger*/genetics , Nanoparticles*/chemistry, Humans ; Animals ; Polymers/chemistry ; Lipids/chemistry ; Gene Transfer Techniques ; Drug Delivery Systems
مستخلص: Developing safe and effective delivery strategies for localizing messenger RNA (mRNA) payloads to the spleen is an important goal in the field of genetic medicine. Accomplishing this goal is challenging due to the instability, size, and charge of mRNA payloads. Here, we provide an analysis of non-viral delivery technologies that have been developed to deliver mRNA payloads to the spleen. Specifically, our review begins by outlining the unique anatomy and potential targets for mRNA delivery within the spleen. Next, we describe approaches in mRNA sequence engineering that can be used to improve mRNA delivery to the spleen. Then, we describe advances in non-viral carrier systems that can package and deliver mRNA payloads to the spleen, highlighting key advances in the literature in lipid nanoparticle (LNP) and polymer nanoparticle (PNP) technology platforms. Finally, we provide commentary and outlook on how splenic mRNA delivery may afford next-generation treatments for autoimmune disorders and cancers. In undertaking this approach, our goal with this review is to both establish a fundamental understanding of drug delivery challenges associated with localizing mRNA payloads to the spleen, while also broadly highlighting the potential to use these genetic medicines to treat disease.
References: Pharmaceutics. 2023 Jan 26;15(2):. (PMID: 36839732)
Langmuir. 2022 Jun 21;38(24):7462-7471. (PMID: 35675506)
Adv Healthc Mater. 2023 Apr;12(9):e2202528. (PMID: 36535635)
Eur J Pharm Biopharm. 2005 Jul;60(2):247-66. (PMID: 15939236)
Mol Ther. 2010 Jul;18(7):1357-64. (PMID: 20461061)
ACS Nano. 2018 Oct 23;12(10):9815-9829. (PMID: 30256609)
J Drug Deliv Sci Technol. 2022 Aug;74:103553. (PMID: 35783677)
Immunity. 2005 Aug;23(2):165-75. (PMID: 16111635)
Nano Lett. 2020 Feb 12;20(2):1117-1123. (PMID: 32003222)
Mol Cell Biol. 2010 Nov;30(21):4996-5008. (PMID: 20823266)
Exp Cell Res. 2020 Nov 1;396(1):112229. (PMID: 32818479)
Angew Chem Int Ed Engl. 2018 Oct 8;57(41):13582-13586. (PMID: 30112821)
J Am Chem Soc. 2023 Sep 13;145(36):19800-19811. (PMID: 37656876)
Int J Mol Sci. 2017 Jun 10;18(6):. (PMID: 28604595)
Small. 2019 Feb;15(6):e1805097. (PMID: 30637934)
ACS Appl Bio Mater. 2023 Nov 6;:. (PMID: 37930174)
Angew Chem Int Ed Engl. 2021 Jun 7;60(24):13280-13286. (PMID: 33751748)
Pharm Res. 2022 Jan;39(1):105-114. (PMID: 35080707)
Adv Healthc Mater. 2023 Jun;12(15):e2202688. (PMID: 36785927)
Mol Ther. 2008 Feb;16(2):333-42. (PMID: 18059369)
MRS Bull. 2021;46(9):832-839. (PMID: 34539057)
Biomacromolecules. 2017 Dec 11;18(12):4307-4315. (PMID: 29141136)
Nat Biotechnol. 2015 Sep;33(9):941-51. (PMID: 26348965)
Genome Biol. 2002;3(3):REVIEWS0004. (PMID: 11897027)
Chem Rev. 2018 Jul 25;118(14):6844-6892. (PMID: 29957926)
Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11. (PMID: 30785039)
Adv Mater. 2016 Apr 20;28(15):2939-43. (PMID: 26889757)
Carcinogenesis. 2006 Jun;27(6):1169-79. (PMID: 16492678)
J Control Release. 2006 May 15;112(2):257-70. (PMID: 16574264)
Macromol Rapid Commun. 2022 Jun;43(12):e2100754. (PMID: 35286740)
Front Immunol. 2020 May 21;11:924. (PMID: 32508825)
Mol Cell Biol. 2001 Mar;21(6):1899-907. (PMID: 11238926)
Annu Rev Immunol. 2022 Apr 26;40:413-442. (PMID: 35113731)
Acc Chem Res. 2014 Dec 16;47(12):3512-21. (PMID: 25310179)
J Gene Med. 2011 Jun;13(6):312-23. (PMID: 21674734)
Bioconjug Chem. 2023 Jul 19;34(7):1177-1197. (PMID: 37431859)
J Immunother. 2011 Jan;34(1):1-15. (PMID: 21150709)
Trends Cell Biol. 2019 Mar;29(3):191-200. (PMID: 30503240)
Adv Drug Deliv Rev. 2022 Sep;188:114416. (PMID: 35787388)
Acc Chem Res. 2022 Jan 4;55(1):2-12. (PMID: 34850635)
Gene Ther. 2001 Aug;8(15):1188-96. (PMID: 11509950)
J Vis Exp. 2016 May 08;(111):. (PMID: 27214391)
Eur J Pharm Sci. 2021 Jun 1;161:105777. (PMID: 33647401)
J Control Release. 2022 May;345:819-831. (PMID: 35346768)
Cold Spring Harb Perspect Biol. 2019 Oct 1;11(10):. (PMID: 30181377)
Cell Cycle. 2011 Jan 15;10(2):229-40. (PMID: 21220943)
Proc Natl Acad Sci U S A. 2023 Jul 4;120(27):e2301067120. (PMID: 37364130)
Int J Mol Sci. 2020 Aug 21;21(17):. (PMID: 32825618)
RNA. 2005 Jul;11(7):1131-40. (PMID: 15929942)
J Mater Chem B. 2022 Jan 5;10(2):236-246. (PMID: 34852030)
ACS Appl Mater Interfaces. 2022 Dec 28;14(51):56440-56453. (PMID: 36525379)
Biomater Sci. 2022 Jan 18;10(2):549-559. (PMID: 34904974)
Mol Ther. 2019 Apr 10;27(4):691-692. (PMID: 30905578)
J Biol Chem. 2004 Mar 26;279(13):12542-50. (PMID: 14729660)
PLoS Genet. 2013;9(10):e1003893. (PMID: 24146636)
PLoS One. 2014 Feb 20;9(2):e88385. (PMID: 24586322)
Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):348-61. (PMID: 21957022)
Pharm Res. 2023 Jan;40(1):27-46. (PMID: 36600047)
Drug Metab Dispos. 2014 Mar;42(3):431-40. (PMID: 24389421)
Int J Mol Sci. 2023 Jan 31;24(3):. (PMID: 36769023)
Trends Cancer. 2019 Apr;5(4):245-262. (PMID: 30961831)
RNA. 2003 Sep;9(9):1108-22. (PMID: 12923259)
ACS Nano. 2023 Dec 26;17(24):24539-24563. (PMID: 38091941)
Nat Nanotechnol. 2020 Apr;15(4):313-320. (PMID: 32251383)
ACS Nano. 2021 Apr 27;15(4):6709-6722. (PMID: 33754708)
Adv Mater. 2017 Sep;29(33):. (PMID: 28681930)
Brief Bioinform. 2023 Jan 19;24(1):. (PMID: 36642413)
Nat Commun. 2022 Mar 22;13(1):1536. (PMID: 35318324)
Acc Chem Res. 2012 Jul 17;45(7):1153-62. (PMID: 22428908)
Nat Rev Drug Discov. 2014 Oct;13(10):759-80. (PMID: 25233993)
Mater Horiz. 2024 Jun 3;11(11):2739-2748. (PMID: 38516806)
Mol Pharm. 2011 Jun 6;8(3):774-87. (PMID: 21417235)
Science. 2022 Jan 07;375(6576):91-96. (PMID: 34990237)
Curr Opin Cell Biol. 1998 Apr;10(2):268-75. (PMID: 9561852)
J Control Release. 2003 Apr 14;89(1):113-25. (PMID: 12695067)
Nano Lett. 2022 Oct 26;22(20):8304-8311. (PMID: 36194390)
Blood. 1985 Nov;66(5):1149-54. (PMID: 4052630)
Front Immunol. 2018 Oct 02;9:2242. (PMID: 30356862)
Curr Rheumatol Rev. 2014;10(1):22-34. (PMID: 25229496)
Biomater Sci. 2021 Feb 21;9(4):1449-1463. (PMID: 33404020)
Explor Target Antitumor Ther. 2022;3(2):117-127. (PMID: 36046844)
Nanomedicine (Lond). 2011 Jun;6(4):715-28. (PMID: 21718180)
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E448-E456. (PMID: 28069945)
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14454-9. (PMID: 17726101)
Angew Chem Int Ed Engl. 2016 Oct 24;55(44):13808-13812. (PMID: 27690187)
Biochem Biophys Res Commun. 2005 May 13;330(3):958-66. (PMID: 15809089)
DNA Res. 2009 Feb;16(1):45-58. (PMID: 19001483)
Chest. 2019 Mar;155(3):605-616. (PMID: 30359614)
Pharm Res. 2011 Sep;28(9):2223-32. (PMID: 21594715)
ACS Cent Sci. 2021 May 26;7(5):748-756. (PMID: 34075344)
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2142-51. (PMID: 27035940)
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5679-84. (PMID: 15824322)
Sci Rep. 2019 Apr 12;9(1):5976. (PMID: 30979970)
Adv Drug Deliv Rev. 2023 Sep;200:115042. (PMID: 37536506)
ACS Cent Sci. 2021 Jul 28;7(7):1191-1204. (PMID: 34341771)
Gene. 2001 Oct 3;276(1-2):73-81. (PMID: 11591473)
Adv Drug Deliv Rev. 2021 Dec;179:114002. (PMID: 34653534)
Adv Mater. 2023 Oct;35(41):e2301686. (PMID: 37165781)
Expert Rev Proteomics. 2010 Dec;7(6):833-48. (PMID: 21142886)
Drug Deliv Transl Res. 2021 Feb;11(1):255-260. (PMID: 32506259)
Mol Cell Toxicol. 2022;18(1):1-8. (PMID: 34567201)
Adv Mater. 2019 Apr;31(14):e1807748. (PMID: 30748040)
Sci Immunol. 2019 Mar 1;4(33):. (PMID: 30824527)
Nucleic Acids Res. 2016 Sep 19;44(16):7511-26. (PMID: 27317694)
Mol Cell. 2016 May 5;62(3):462-471. (PMID: 27153541)
ACS Appl Mater Interfaces. 2023 Apr 26;15(16):19937-19950. (PMID: 37052212)
RNA. 2001 Oct;7(10):1486-95. (PMID: 11680853)
Pharmaceutics. 2021 Jan 19;13(1):. (PMID: 33478077)
RNA Biol. 2018;15(6):756-762. (PMID: 29578372)
Biomater Sci. 2019 Jun 25;7(7):2640-2651. (PMID: 31090764)
Adv Mater. 2022 Apr;34(16):e2201095. (PMID: 35218106)
Biomater Sci. 2018 Nov 1;6(11):3009-3018. (PMID: 30264063)
Pharmaceuticals (Basel). 2022 Aug 18;15(8):. (PMID: 36015165)
Trends Biotechnol. 2004 Jul;22(7):346-53. (PMID: 15245907)
Toxicol Pathol. 2006;34(5):455-65. (PMID: 17067939)
Blood. 2006 Dec 15;108(13):4009-17. (PMID: 16940422)
Immunity. 2013 Nov 14;39(5):806-18. (PMID: 24238338)
Nucleic Acids Res. 2014;42(16):10245-64. (PMID: 25150148)
Angew Chem Int Ed Engl. 2023 Oct 26;62(44):e202310395. (PMID: 37651468)
Diabetes. 2021 Dec;70(12):2892-2902. (PMID: 34620616)
Signal Transduct Target Ther. 2021 May 31;6(1):213. (PMID: 34059617)
Nat Biotechnol. 1996 Nov;14(11):1574-8. (PMID: 9634824)
RNA. 2006 May;12(5):851-61. (PMID: 16540693)
Front Immunol. 2020 May 08;11:760. (PMID: 32457742)
Clin Cancer Res. 2020 Aug 1;26(15):3901-3907. (PMID: 32332013)
Mol Ther. 2003 Dec;8(6):936-47. (PMID: 14664796)
Adv Mater. 2021 Aug;33(34):e2101707. (PMID: 34278613)
J Am Chem Soc. 2023 May 24;145(20):11375-11386. (PMID: 37184377)
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):187-203. (PMID: 11259840)
Theranostics. 2024 Jan 1;14(1):1-16. (PMID: 38164140)
Beilstein J Org Chem. 2017 Dec 20;13:2819-2832. (PMID: 30018667)
Pharm Res. 2013 Feb;30(2):342-51. (PMID: 22983644)
Cytokine Growth Factor Rev. 2008 Feb;19(1):3-19. (PMID: 18248767)
Nanoscale. 2019 Nov 21;11(45):21733-21739. (PMID: 31713568)
BMC Bioinformatics. 2001;2:2. (PMID: 11472630)
Immunity. 2022 Nov 8;55(11):1993-2005. (PMID: 36351374)
Adv Drug Deliv Rev. 2021 Dec;179:114000. (PMID: 34637846)
J Control Release. 2017 Jun 28;256:79-91. (PMID: 28411182)
Mol Pharm. 2022 Apr 4;19(4):1047-1058. (PMID: 35238565)
Annu Rev Med. 2023 Jan 27;74:339-352. (PMID: 35804480)
Semin Cell Dev Biol. 2014 Oct;34:24-32. (PMID: 24910447)
Cardiovasc Hematol Disord Drug Targets. 2018;18(1):61-70. (PMID: 29422010)
Eur J Immunol. 2008 Aug;38(8):2263-73. (PMID: 18651710)
Nature. 2011 May 19;473(7347):337-42. (PMID: 21593866)
Clin Immunol Immunopathol. 1983 Oct;29(1):1-6. (PMID: 6411402)
Nat Protoc. 2023 Jan;18(1):265-291. (PMID: 36316378)
Science. 2021 Jan 8;371(6525):145-153. (PMID: 33414215)
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5859-E5866. (PMID: 29891683)
Cell. 2009 Feb 20;136(4):763-76. (PMID: 19239894)
J Biol Chem. 1997 Apr 18;272(16):10448-56. (PMID: 9099687)
Science. 2006 Nov 10;314(5801):994-7. (PMID: 17038590)
Adv Mater. 2018 May 7;:e1705328. (PMID: 29736981)
Chem Rev. 2021 Sep 22;121(18):11527-11652. (PMID: 33939409)
Int J Pharm. 2019 Mar 10;558:128-142. (PMID: 30639218)
Mol Cancer. 2021 Feb 25;20(1):41. (PMID: 33632261)
Neurobiol Dis. 2014 Dec;72 Pt A:3-12. (PMID: 25173806)
Expert Opin Drug Deliv. 2022 Dec;19(12):1650-1663. (PMID: 36377494)
Toxicol Pathol. 2006;34(5):648-55. (PMID: 17067950)
Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):. (PMID: 34933999)
Pharmaceuticals (Basel). 2022 Jul 20;15(7):. (PMID: 35890195)
J Control Release. 2006 Aug 10;114(1):100-9. (PMID: 16831482)
معلومات مُعتمدة: K12 TR004416 United States TR NCATS NIH HHS; R21 EB034942 United States EB NIBIB NIH HHS
المشرفين على المادة: 0 (RNA, Messenger)
0 (Polymers)
0 (Lipids)
تواريخ الأحداث: Date Created: 20240507 Date Completed: 20240611 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC11175841
DOI: 10.1039/d4bm00038b
PMID: 38712531
قاعدة البيانات: MEDLINE
الوصف
تدمد:2047-4849
DOI:10.1039/d4bm00038b